Dr. Thomas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
28 York Road
Winchester, MA 01890
Education & Training
- University of California, Irvine, School of MedicineClass of 1996
Certifications & Licensure
- CA State Medical License 2001 - 2027
- OH State Medical License 2002 - 2025
- PA State Medical License 2009 - 2024
Publications & Presentations
PubMed
- 88 citationsIndium-111–Capromab Pendetide Radioimmunoscintigraphy and Prognosis for Durable Biochemical Response to Salvage Radiation Therapy in Men After Failed ProstatectomyCherry T. Thomas, Patrick T. Bradshaw, Bradley H Pollock, James E. Montie, Jeremy M. G. Taylor
Journal of Clinical Oncology. 2003-05-01 - 3 citationsA positron-emitting internal marker for identification of normal tissue by positron emission tomography: phantom studies and validation in patients.Cherry T. Thomas, Charles R. Meyer, Robert A. Koeppe, Gregory P. Kalemkerian, Susan J. Fisher
Molecular Imaging and Biology. 2003-03-01
Press Mentions
- Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007March 19th, 2025
- Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic LymphomaNovember 12th, 2024
- Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin LymphomaJuly 12th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: